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Abstract
Background: Life-threatening infections with type B Coxsackieviruses (CV-B) are frequently encountered among
newborns and are partly attributed to vertically-transmitted virus. Our current study investigates this alternative way
of contamination by CV-B, using a mouse model.
Methods: Pregnant Swiss mice were intraperitoneally inoculated with CV-B4 E2 at gestational day 10(G) or 17G.
Dams and offspring were monitored for mortality and morbidity, and sampled at different time-points to document
the infection and explore eventual vertical transmission.
Results: Inoculation at day 10G induced an important rate of abortion and a decrease in the number of delivered
pups per litter, whereas inoculation at day 17G was marked by preterm delivery and significant behavioral changes
in dams. Only one case of spastic paralysis and one case of pancreatitis were recorded among surviving pups.
Seroneutralization revealed anti-CV-B4 neutralizing antibodies in infected dams and their partial transfer to offspring.
Viral genome detection by RT-PCR and viral progeny titration in several tissues (dams’ uteri, amniotic sac, amniotic
fluid, placenta, umbilical cord, pancreas and heart) attested and documented CV-B4 vertical transmission to the
majority of analyzed offspring. Virus detection in fetuses suggests transplacental transmission, but perinatal
transmission during delivery could be also suggested. Vertically transmitted CV-B might even persist since
prolonged viral RNA detection was noticed in the pancreas and heart from offspring born to dams inoculated at
day 17G.
Conclusion: This model of CV-B4 vertical transmission in mice, in addition to allow a better understanding of CV-B
infections in fetuses and newborns, constitutes a useful tool to investigate the pathogenesis of CV-B associated
chronic diseases.
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Background
Type B Coxsackieviruses (CV-B) are common encoun-
tered pathogens that, although mostly limited to asymp-
tomatic and subclinical infections, are known for their
wide tropism and for their broad spectrum of associated
diseases (reviewed in [1]). Indeed, when the infection is
symptomatic, it is generally localized to the gastrointes-
tinal tract (the primary site of replication for those en-
teric viruses), and more rarely to the oropharynx. When
virus replication persists despite the immune response,
the virus reaches the blood circulation through mesen-
teric lymph nodes, then several target tissues such as
heart, pancreas, spleen, liver, spinal cord, etc. Indeed,
CV-B have been associated to several acute (meningitis,
myocarditis, pancreatitis, encephalitis) and chronic dis-
eases (chronic myocarditis, dilated cardiomyopathy, type
1 diabetes) that are often severe, even life-threatening,
particularly in newborns and young children, thus con-
stituting a serious public health problem [1–3].
The six CV-B serotypes (CV-B1 to 6) belong to the
Enterovirus B species, from the Enterovirus genus (actu-
ally encompassing at least 271 human serotypes distrib-
uted in 7 species), of the Picornaviridae family [4, 5].
They are small, non-enveloped, icosahedral, positive-
sense single-stranded RNA viruses.
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Due to their resistance in the environment, CV-B are
essentially transmitted through the fecal-oral mode, and
occasionally through the respiratory route [6]. The high
frequency of CV-B infections among neonates however
suggests a possible vertical transmission of those viruses,
at least in some cases [3, 7]. Several epidemiological,
serological and virological arguments are in favor of this
hypothesis. Indeed, increased levels of anti-CV-B anti-
bodies have been found in pregnant women in associ-
ation with an infection of the offspring [8, 9]. The viral
genome has also been detected in maternal and offspring
tissues [2, 9, 10]. Vertical transmission of CV-B may
occur either in utero (antenatally) through the transpla-
cental way [11], or perinatally during delivery [9].
CV-B vertical transmission has been associated to an
elevated risk of abortion [8, 10, 12–15] and stillbirth [16,
17]. In the case of live birth, vertically transmitted CV-B
seem largely involved in many life-threatening diseases
affecting fetuses, newborns and young infants [2, 3, 7,
18, 19]. On the basis of the presence of a viremia or the
appearance of clinical symptoms, about 22% of fatal CV-
B infections of the neonates, result from an intra-uterine
infection [7]. Moreover, maternal CV-B infections during
pregnancy would predispose offspring to the develop-
ment of autoimmune diseases such as type 1 diabetes
[20]. Infections with CV-B during pregnancy are how-
ever generally neglected compared to those by other
pathogens such as rubella virus, Zika virus, Toxoplasma,
etc.….
Considering the frequency of that mode of contamin-
ation by CV-B, the width and the severity of its conse-
quences, CV-B vertical transmission deserves further
investigation, in an attempt to develop preventive and/or
therapeutic strategies. In this context, our current study




The diabetogenic strain CV-B4 E2 (kindly provided by J.
W. Yoon, Julia McFarlane Diabetes Research Centre,
Calgary, Alberta, Canada) was propagated in HEp-2 cells
(BioWhittaker, Walkersville, MD, USA) in Eagle’s min-
imal essential medium (MEM; Gibco BRL, Invitrogen,
Gaithersburg, MD, USA) supplemented with 10% heat-
inactivated fetal calf serum (FCS; Gibco BRL), 1%
(2 mM) L-glutamine (BioWhittaker), 50 μg/ml strepto-
mycin, 50 IU/ml penicillin (Gibco BRL), 1% non-
essential amino-acids (Gibco BRL), and 0.05% (2.5 μg/
ml) fungizone (Amphotericin B, Apothecon). Superna-
tants were collected 3 days post-inoculation (p.i.), clari-
fied by centrifugation at 2000 × g for 10 min, divided
into aliquots, and stored at −80 °C. Virus titers in stocks
were determined on HEp-2 cells by limiting dilution
assay for 50% tissue culture infectious doses (TCID50) by
the method of Reed and Muench [21].
Mice
All animals used in this investigation were handled in
the animal facility of the Faculty of Pharmacy of Monas-
tir, in accordance with the standards of general ethics
guidelines, and maintained in specific “pathogen-free”
conditions with unlimited access to food and water.
Adult outbred Swiss albino mice (Pasteur Institute,
Tunis) were mated (three females per male were caged
together) until successful fertilization (through forma-
tion of a vaginal plug) was checked. The day the vaginal
plug was observed was considered the first day of gesta-
tion (day 1G).
Mice inoculation and follow-up
Pregnant mice were inoculated intraperitoneally at two
different time points, either at day 10 or 17 of gestation
(day 10G or 17G), with 2 × 105 TCID50 CV-B4 E2 units
contained in 200 μl culture medium. Naïve mice served
as negative controls. Pregnancy was monitored by daily
weighing from day 10G until delivery. Animals were also
observed for mortality, morbidity and behavioral
changes. Offspring born to dams inoculated at day 10G
were sacrificed, using isoflurane, at day 17G and days 0
and 5 from birth (six offspring at each time point, each
three born to one different dam). By the same, those
born to dams inoculated at day 17G were sacrificed
(only if delivery occurred at least 2 days later (starting
from day 19G)) at days 0 and 5 from birth, then later at
days 21, 30, 50 and 70 (since, as suggested by the find-
ings of Bopegamage et al., [22], inoculation at that preg-
nancy stage would have an effect easier to observe in
older offspring). Amniotic fluids, placentas, internal or-
gans from fetuses and newborn pups, then blood sam-
ples from the tail vein (for dams and for offspring at
least 21 days old) were used for anti-CV-B4 antibody ti-
tration by seroneutralization. Dams’ uteri, as well as um-
bilical cords, amniotic sacs, amniotic fluids and
placentas were collected whenever possible (at day 17G),
as key tissues in vertical transmission. Offspring’s pan-
creases and hearts, spleens and small intestines were also
collected. Sampled tissues were rinsed with cold PBS (to
remove eventually contaminating blood) and treated for
histological examination, viral RNA detection and pro-
geny titration (spleens and small intestines were used
only for histological examination).
Histological analysis
Formalin-fixed, paraffin-embedded tissues (dams’ uteri,
and offspring’s placentas, pancreases, hearts, spleens and
small intestines) were subjected to histological examination
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following hematoxylin/eosin staining, as described
elsewhere [23].
Antibody titration by seroneutralization
Blood sampling being impossible in fetuses (sampled at
day 17G) and newborn pups (sampled at days 0 and 5
from birth), we used the whole set of internal organs
that were homogenized in an equal volume of sterile 1%
penicillin/streptomycin PBS used beforehand for rinsing
inside the animal after dissection. Placentas were proc-
essed separately. After 15 min of centrifugation at 900 ×
g, the recovered supernatants were used for antibody ti-
tration, as the amniotic fluids (two samples, each one
being a pool of the amniotic fluids of the three fe-
tuses belonging to the same litter) and the sera (ob-
tained after centrifugation of the blood sampled from
dams and offspring of 21 days and older), following a
recently described procedure [24]. The neutralizing
titer was defined as the reciprocal of the last dilution
of sample that totally inhibited the viral cytopathic ef-
fect (CPE) as observed under an inverted microscope.
Results are plotted as mean neutralizing titers ± stand-
ard deviations (SDs).
Viral genome detection
For each experimental condition (virus inoculation at
day 10G, or 17G, and in the absence of virus inocula-
tion), the presence of CV-B4 E2 RNA was checked at
different p.i. times in the pancreas and heart of six
mice (three offspring born to each of two dams) and,
whenever possible (at day 17G), in placentas, amniotic
fluids, and dams’ uteri, according to the procedure
described below.
RNA extraction
Washed and snap-frozen tissues were homogenized by
crushing in Tri-Reagent (Sigma), and then centrifuged at
12,000 × g for 10 min at 4 °C. Recovered supernatants
were then subjected to total RNA extraction by the acid
guanidium thiocyanate-phenol-chloroform procedure, as
described by Chomczynski and Sacchi [25]. Sterile
nuclease-free water and supernatant of CV-B4 E2-
infected HEp-2 cells, submitted to the same extraction
procedure, served as negative and positive controls, re-
spectively. Extracted RNA was then dissolved in 50 μl of
nuclease-free water (Promega), quantified using the
Nanodrop 2000 (UV–Vis Spectrophotometer, Thermo
Scientific) and stored at −80 °C until use in reverse tran-
scription (RT)-PCR assays.
Two-step RT-PCR for CV-B4 E2 RNA detection
For CV-B4 E2 RNA amplification, we used primer sense
008 : 5′-GAGTATCAATAAGCTGCTTG-3′ and anti-
sense 007: 5′-ATTGTCACCATAAGCAGCCA-3′ specific
of the highly conserved 5′NC region of enterovirus gen-
ome and generating a 414 bp fragment [26].
cDNA synthesis was performed with about 100 ng of
RNA using 0.1 μM of the anti-sense 007 primer and the
M-MLV reverse transcriptase (Invitrogen), according to
the manufacturer’s instructions.
The PCR was carried out with 3 μl of cDNA samples
and 0.4 μM each primer in a total volume of 50 μl con-
taining 2.5 U of Taq Paq5000 DNA Polymerase (Agilent
technologies), 0.2 mM each dNTP and 2 mM MgCl2.
The PCR mixture was subjected to a first denaturation
step for 3 min at 94 °C, followed by 30 cycles of amplifi-
cation, consisting of denaturation for 20 s at 94 °C, an-
nealing for 20 s at 55 °C, and extension for 30 s at 72 °C,
followed by a final extension step for 5 min at 72 °C. All
reactions were performed by using a preheated Eppen-
dorf thermal cycler.
RNA extracted from supernatant of CV-B4 E2-
infected HEp-2 cells was reverse transcribed, and
amplified according to the same procedure described
above, and served as a positive control. A negative
control (no RNA) was also included in each reaction.
Samples showing negative results were subjected to
beta-actin mRNA amplification, as an internal control
to ensure the integrity of extracted RNA and the ab-
sence of RT-PCR inhibitors.
Semi-nested (sn)-PCR
RT-PCR products showing negative results were sub-
jected to a subsequent sn-PCR with internal primer
sense 006: 5′-TCCTCCGGCCCCTGAATGCG-3′ and
antisense primer 007, generating a 155 bp fragment [27].
The similar reaction mix and the same cycling program
were used, except that the annealing temperature was
60 °C. A positive control (DNA amplified from the RNA
extract of supernatant of CV-B4 E2-infected HEp-2
cells) and a negative control (no DNA) were included in
each reaction.
Viral progeny titration
For each experimental condition (virus inoculation at
day 10G, or 17G, and in the absence of virus inocula-
tion), infectious virus titration was performed, by the
limiting dilution method, at different p.i. times (day 17G
and days 0 and 5 from birth) in the pancreas and heart
of six mice (three offspring born to each of two dams)
and, whenever possible (at day 17G), in uteri, umbilical
cords, amniotic sacs, amniotic fluids and placentas, ac-
cording to the procedure described below. Briefly, snap-
frozen tissues were weighed and crushed in 1% penicil-
lin/streptomycin PBS, and then centrifuged at 12,000 × g
for 10 min at 4 °C. Supernatants were diluted 10-fold in
MEM with 2% FCS, inoculated (100 μl) onto confluent
HEp-2 cells (104 cells/well) in 96-well culture plates.
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Cultures were incubated at 37 °C in a humidified atmos-
phere with 5% CO2 and examined daily for CV-B4 CPE
up to 7 days p.i.. Cells were then stained with crystal vio-
let for 30 min. Finally, wells were rinsed with water and
plates were examined for the highest dilution showing
CPE. Viral titers were calculated according to the
method of Reed and Muench [21], and expressed as
mean titers (TCID50/mg of tissue) ± SDs.
Statistical analysis
Data are summarized as means ± SDs. The two-sided
paired Student’s t test was used to compare the mean
weight, at different time points, between infected and
control animals. The Wilcoxon rank-sum test was used
to compare the number of pups per litter between in-
fected and control animals, as well as neutralizing anti-
body titers between offspring born to dams inoculated at
either day 10G or 17G. Statistical significance was de-
fined by P-values less than 0.05.
Results
Effect of CV-B4 E2 on pregnancy outcome
Pregnant mice were monitored by daily weighing from day
10G until delivery. Thus, starting from day 17G, we observed
a significant decrease (p= 0.003) in the weight of dams inocu-
lated with CV-B4 E2 at day 10G compared to negative con-
trol pregnant dams (Fig. 1a). The weight of mice inoculated
at day 17G remained however, until delivery, comparable to
the one of negative control mice (Fig. 1a).
That decrease in the weight of dams inoculated at day
10G was associated to a high rate of abortion (53%) (Fig. 1b)
and to a 37% reduction in the number of offspring per litter
in the remaining cases compared to negative control dams
(5.77 ± 0.93 vs. 9.25 ± 1.04, p = 0.0001, Fig. 1c).
No pregnancy loss was observed among dams inocu-
lated at day 17G and the number of offspring per litter
was comparable to the one in negative control dams
(8.7 ± 0.97 vs. 9.25 ± 1.04, Fig. 1c), but delivery occurred
earlier since it never exceeded day 20G (days 17G, 18G,
19G and 20G in 27, 36, 27 and 10% of the cases, respect-
ively, versus day 21G to 22G in the negative control
group and in dams inoculated at day 10G) (Fig. 1a).
In addition, as soon as delivery, 33% of dams inocu-
lated at day 17G were characterized by an unusual be-
havior, even aggressivity, which respectively manifested
through abandon of their litter (pups are abandoned
with their placentas and their wastes and are not breast-
fed), and through killing and devouring their pups.
Effect of CV-B4 E2 on offspring
No signs of morbidity were observed among offspring
from CV-B4 E2-inoculated dams, except one case of
spastic paralysis in a neonate pup coming from virus in-
oculation at day 10G.
At the microscopic level, histopathological analysis re-
vealed a unique case of pancreatitis with fatty degener-
ation of acinar cells on a section of a pancreas sampled
at day 30 after birth in an offspring born to a dam inoc-
ulated with CV-B4 E2 at day 17G (Fig. 2).
CV-B4 E2 vertical transmission
Detection of anti-CV-B4 neutralizing antibodies in virus-
inoculated dams and their offspring
Before talking about a vertical transmission of CV-B4, it
was essential to verify the infection of inoculated dams.
Fig. 1 Effect of CV-B4 E2 on pregnancy outcome. a Evolution of the
mean body weight of dams during pregnancy depending on whether
they were inoculated or not with CV-B4 E2, and at each gestational day.
(Results are representative of an experiment with n= 3 for negative control
mice, n= 7 for dams inoculated with CV-B4 E2 at day 10G, and n= 5 for
dams inoculated with CV-B4 E2 at day 17G). b Evolution of the mean body
weight of dams inoculated at day 10G depending on whether there was
pregnancy loss or not (Results are representative of an experiment with
n= 4 and n= 3, respectively). c Variation of the number of offspring per
litter depending on the inoculation period. (n= 9 for negative controls,
n= 13 for mice inoculated at day 10G, and n= 10 for mice inoculated at
day 17G)
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For this purpose, we searched for anti-CV-B4 neutraliz-
ing antibodies in the sera of dams inoculated either at
day 10G (6 dams, 2 per time point) or day 17G (4 dams,
2 per time point) (Fig. 3a). Inoculation at day 10G re-
sulted in important neutralizing titers that peaked by
day 0 (≥1280, 11 to 12 days p.i.), then rapidly decreased
thereafter (40 by day 5 after birth). Inoculation at day
17G induced low neutralizing titers (20) detectable by
day 0 (only when delivery occurred at day 20G, 3 days
p.i.) that increased thereafter (≥1280) at day 5 and later
(day 21, data not shown).
Four out of the six placentas sampled at day 17G re-
vealed positive for anti-CV-B4 neutralizing antibodies
(mean titer 226.67), whereas both pooled amniotic fluids
revealed negative.
Anti-CV-B4 neutralizing antibodies could also be
found in offspring born to the above analyzed dams, in-
oculated either at day 10G or 17G (Fig. 3b). Mean neu-
tralizing titers whilst being non-significantly higher in
offspring born to dams inoculated at day 10G, where
relatively low in both cases in the beginning but
Fig. 2 Histopathological changes in offspring born to dams inoculated
with CV-B4 E2. Pancreas, Heart, spleen and small intestine sections of
six offspring (each three born to one different dam) from each of con-
trol dams and dams inoculated with CV-B4 E2, either at day 10G or
17G, were analyzed by hematoxylin/eosin staining at different p.i.
times. Histopathological changes were found only in one pancreas of
an offspring born to a dam inoculated at day 17G and sampled 30 days
post-partum (b). Inflammatory foci and fatty degeneration of acini are
indicated by little and large arrows, respectively. No anomalies were
observed in all other analyzed sections. Representative microscopic
observation of a pancreas section from a negative control offspring
taken at day 30 post-partum (a). Gr ×400
Fig. 3 Kinetics of anti-CV-B4 neutralizing antibodies after virus
inoculation of pregnant dams. In order to evaluate the presence and
the amount of anti-CV-B4 neutralizing antibodies, seroneutralization
was performed at different time-points on (a): sera from dams
inoculated with CV-B4 E2 at either day 10G or 17G, (b): supernatants of
homogenized internal tissues from offspring born to dams inoculated
with CV-B4 E2 at either day 10G or 17G and (c): sera from offspring
(at least 21 days old) born to dams inoculated with CV-B4 E2 at day
17G. Results are plotted as mean neutralizing titers ± SD, n = 2 for dams
and n = 6 for offspring. The proportion of seropositive animals is indicated
on each bar. Neutralizing antibodies were not detected in any sample
from all negative control mice
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progressively increased with the increase in the propor-
tion of seropositive animals (up to days 5 and 21 in off-
spring born to dams inoculated at days 10G and 17G,
respectively). Mean neutralizing titers then decreased
over time with the decrease in the proportion of sero-
positive animals, but were still measurable 90 days after
birth in offspring born to dams inoculated at day 17G
(not performed in those born to dams inoculated at day
10G) (Fig. 3c).
No neutralizing activity could be evidenced in samples
from negative control animals (dams and their offspring).
Detection of CV-B4 genome in tissues from virus-inoculated
dams and their offspring
The presence of viral RNA was investigated in selected
key tissues for vertical transmission (uterus, amniotic
fluid and placenta sampled at day 17G), as well as in
CV-B4 privileged targets, namely pancreas and heart.
Table 1 summarizes the results of RT-PCR and sn-RT-
PCR in those tissues sampled at different p.i. times, from
two dams and three offspring of each, as described in
the Methods section.
Thus, CV-B4 E2 RNA was detected in 2/2 uteri, 1/2
amniotic fluids and 3/6 placentas, sampled at day 17G
from animals inoculated at day 10G. Evidently, animals
inoculated at day 17G were not sampled at that time
point.
As regards the privileged target tissues of CV-B4 E2,
viral RNA was found in all (18/18) pancreases sampled,
from day 17G through day 5 after birth, in offspring
born to dams inoculated at day 10G, and in 11/12 pan-
creases, sampled at days 0 and 5, in offspring born to
dams inoculated at day 17G. Regarding the heart, 14/18
and 10/12 tissues, sampled up to day 5, were positive for
CV-B4 E2 RNA in the case of inoculation at day 10G or
day 17G, respectively.
These findings reveal CV-B4 E2 vertical transmission to
18/18 offspring born to dams inoculated at day 10G, and
to 11/12 offspring born to dams inoculated at day 17G.
However, as mentioned in the Methods section, pups
born to dams inoculated at day 17G were followed for a
longer period (up to day 70 after birth), to address the
issue of an eventual persistence of the virus. As summa-
rized in Table 2, CV-B4 E2 RNA was detected until
70 days after birth in 8/15 pancreases sampled from day
21 through day 70, and until 50 days after birth in 7/15
hearts sampled at the same time points, thus revealing
10/15 additional offspring infected through vertical
transmission of the virus from dams inoculated at day
17G (total 21/27).
Some samples required a subsequent sn-PCR round to
reveal positive for viral RNA (22 among a total of 74
positive samples (29.73%)).
Viral RNA was not found in samples from negative
control dams and offspring.
Detection of infectious CV-B4 particles in tissues from
virus-inoculated dams and their offspring
To better document the infection, a variety of tissues
were analyzed for the presence of infectious virus, at
Table 1 RT-PCR results for viral RNA detection in several tissues following CV-B4 E2 inoculation
Sampling Day 17G Day 0 Day 5
Inoculation at day 10G Dams Uterus +* Litter 1
+ Litter 2
Offspring Amniotic fluid +* Litter 1
- Litter 2
Placenta +* - - Litter 1
+ + - Litter 2
Pancreas + +* + + +* +* + + +* Litter 1
+ + + +* +* + + + + Litter 2
Heart - + + + + +* + + + Litter 1
+ - - +* + + + + - Litter 2
Inoculation at day 17G Offspring Pancreas + +* + + + + Litter 1
+ + - + + + Litter 2
Heart +* + - + + +* Litter 1
+* +* - + + + Litter 2
pup 1 pup 2 pup 3 pup 1 pup 2 pup 3 pup 1 pup 2 pup 3
Uteri from two pregnant dams inoculated at day 10G, together with amniotic fluid (pool) and placentas of three offspring of each dam, were sampled at day 17G.
Pancreases and hearts from six offspring (each three born to one different dam) were sampled at each of days 17G, and 0 and 5 post-partum when dams were
inoculated at day 10G, and at days 0 and 5 post-partum when dams were inoculated at day 17G. Results are summarized as positive (+) or negative (-). * Result
obtained by sn-RT-PCR
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different time points, as described in the Methods sec-
tion. A viral progeny could be evidenced in samples
taken from several tissues of dams inoculated at day
10G and their offspring, namely pancreas and heart but
also umbilical cord, placenta, amniotic sac, uterus and
amniotic fluid (sampled only at day 17G) (Fig. 4a). The
most elevated titers were recovered from pancreas,
heart, umbilical cord, placenta, then amniotic sac, uterus
and amniotic fluid. The mean viral titers decreased (even
nullified in the pancreas) by day 0, then increased by day
5 after birth. As regards virus inoculation at day 17G,
only offspring pancreases and hearts were analyzed and
a viral progeny could also be evidenced at both day 0
and day 5 from birth (Fig. 4b). The mean viral titers in-
creased between day 0 and day 5 and, pancreases
showed higher titers than hearts.
Discussion
Vertical transmission is a way of contamination by CV-B
that, despite constituting a serious problem, as explained
above, is not sufficiently recognized and not thoroughly
investigated. Most of our current knowledge on this sub-
ject comes from clinical observations in humans. Few in-
vestigations on CV-B vertical transmission were carried
on mice [22, 28–33], an experimental tool however
frequently used to explore various aspects of infection
by those viruses, difficult to address in humans. Different
viral and mice strains were used, together with different
inoculation periods and routes, as well as different
methods of analysis. Altogether, those studies generated
numerous data, but the issue of CV-B vertical transmis-
sion is not totally elucidated and disserves further work.
It is in this context that joins our current study.
As in a previous study [26], we performed our experi-
ments with the outbred Swiss albino mouse strain for a
better representation of the heterogeneity inside the hu-
man population. We equally used the viral strain CV-B4
E2 that revealed to target numerous tissues.
The time of inoculation during pregnancy was an im-
portant point to consider since, according to previous
studies, it seems to highly influence the outcome of CV-
B infection in offspring [22, 28, 31–33]. Indeed, Dalldorf
and Gifford [28], who were the first to investigate CV-B
vertical transmission in mice, noticed that CV-B1 pan-
creatic line intraperitoneally inoculated to mice of the
Albany Standard strain in the third week of gestation,
resulted in an increase in the morbidity/mortality rate
among offspring (from 20 to 43% in the first and second
week, respectively, to 77% in the third week), and thus
to an increase in the severity of the infection at that
Table 2 RT-PCR results for prolonged viral RNA detection in pancreas and heart following CV-B4 E2 inoculation at gestational day 17
Day 21 Day 30 Day 50 Day 70
Pancreas +* - - + + - - + +* + - - Litter 1
- + + Litter 2
Heart +* - - + +* - + +* - - - - Litter 1
+* + - Litter 2
pup 1 pup 2 pup 3 pup 1 pup 2 pup 3 pup 1 pup 2 pup 3 pup 1 pup 2 pup 3
Pancreases and hearts from six or three offspring (each three born to one different dam) were sampled at each of days 21, 30, 50 and 70 post-partum. Results are
summarized as positive (+) or negative (-). * Result obtained by sn-RT-PCR
Fig. 4 Kinetics of viral progeny in several tissues following CV-B4 E2 inoculation at either gestational day 10 (a) or 17 (b). Uteri from two pregnant
dams inoculated at day 10G, together with amniotic sacs, amniotic fluids (pool), umbilical cords and placentas of three offspring of each dam, were
sampled at day 17G. Pancreases and hearts from six offspring (each three born to one different dam) were equally sampled at each of days 17G, and 0
and 5 post-partum when dams were inoculated at day 10G, and at days 0 and 5 post-partum when dams were inoculated at day 17G. Samples were
subjected to viral progeny titration by the Reed and Muench’s method as described in the Methods section. Results are plotted as mean TCID50/mg
(except for the amniotic fluid where they are expressed as mean TCID50/ml)± SD, n = 6. No trace of viral progeny could be evidenced in any tissue from all
the negative control animals
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stage. Conversely, Lansdown [31] reported that intra-
muscular CV-B3 inoculation of Swiss mice during the
first week of gestation (day 4G or 8G) induces more
pregnancy loss than an inoculation of the same virus
during the second week (day 12G). Here, fetal wastage
was attributed to the nutritive deficit resulting from de-
struction of the maternal exocrine pancreas by the virus.
By the same, in the investigation carried by Modlin and
Crumpacker [32] with outbred CD-1 mice, oral inocula-
tion with CV-B1 in the first week of gestation (day 7G),
despite causing a less severe infection in dams, induced
significantly more abortions than inoculation in the third
week (day 14G and 16G). In another investigation, also
carried on CD-1 mice, maternal oral inoculation by CV-
B4 E2 at day 4G or day 17G had little effect on preg-
nancy outcome, whereas infection at day 10G affected
dams and/or offspring [22]. In that same study, inocula-
tion at day 17G predisposed to an aggravation of the
consequences (severe pancreatic inflammations and
hyperglycemia) of a post-natal challenge of pups by the
same viral strain [22]. That difference in susceptibility to
infection along the different gestational periods was at-
tributed to physiological changes in hormonal rates that
would be associated to a decrease in immunity [28, 32].
Variations in the level of expression of the Coxsackie/
Adenovirus receptor (CAR) protein, which revealed to
be an essential molecule for the embryonic development
[34, 35], can also explain that difference in susceptibility
to CV-B infection during the different stages of gesta-
tion. Being inspired by the results of Bopegamage et al.,
[22] working with the same viral strain as well as out-
bred mice, we chose to inoculate our mice at day 10G
(second week) and 17G (third week of gestation).
As illustrated in the Results section, inoculation at day
10G, but not at day 17G, was followed by a significant
weight loss in pregnant dams associated to an important
rate of abortion and a reduced number of offspring per
litter, which is in agreement with what has been ob-
served previously [22, 28]. A reduction in the mean body
weight of newborn pups was also noticed following virus
inoculation at day 10G (data not shown) which is remin-
iscent of what was previously reported in fetuses sam-
pled at the end of pregnancy following maternal
inoculation at day 8G [31, 36]. Weight loss could just re-
flect morbidity among infected animals or at least
changes on their state of health.
Such consequences were not observed following in-
oculation at day 17G, maybe because the infection oc-
curs too late during pregnancy to affect its outcome.
Inoculation at that gestational stage seems however to
have more effect on dams, here manifesting through
premature delivery, then unusual behavior (possibly be-
cause delivery occurs during the acute phase of the in-
fection). An increase in susceptibility of dams to CV-B
infection with advancing pregnancy has already been de-
scribed by other teams [28, 32]. Cannibalism (destruc-
tion of litters by their mothers) at birth has equally been
reported in one of those studies together with evident
morbidity of dams for at least 1 week postpartum [28].
No delay in the fetal growth could however been evi-
denced as previously reported by others [36, 37], what-
ever was the inoculation period. By the same, morbidity
among offspring manifested only in two cases in the
current investigation (one case of paralysis, and one case
of pancreatitis), which is negligible if we consider the
total number of examined pups, and reminiscent of the
results of Bopegamage et al., [22] that observed normal
histology and normal blood glucose levels in offspring
born to CV-B4 E2-inoculated dams.
In order to document CV-B4 E2 infection, we began
with a rather simplistic approach, namely the detection
of anti-CV-B4 antibodies by seroneutralization. Indeed,
numerous studies documented a neutralizing response
in CV-B-inoculated mice, a response that, as in humans,
can be considered as an indirect proof of infection [24,
38, 39]. It has been previously reported that 90% of preg-
nant CD-1 outbred Swiss mice orally inoculated with
CV-B3, late in pregnancy, developed IgG antibodies to
CV-B3 starting from 5 days p.i. [33]. Those antibodies
seemed to protect offspring against postnatal mortality,
but not against stillbirth. To the best of our knowledge,
only two studies already reported maternal transfer of
anti-CV-B antibodies to offspring in mice, and the effect
of such antibodies seems rather contradictory and dis-
serves further investigation [22, 40]. Indeed, passively
transferred maternal antibodies enhanced the infection
of offspring during challenge in the investigation of
Bopegamage et al., [22], whereas they protected chal-
lenged offspring from infection in the work of Larsson
et al., [40]. In our current work, anti-CV-B4 antibodies
were retrieved in fetuses (day 17G) and, even after birth,
roughly maintained at lower levels than in dams, which
suggests a partial transplacental transfer (as strength-
ened by antibodies detection in the placenta) of maternal
antibodies. The progressive increase in the number of
seropositive pups, then their decrease after day 21, let us
equally think about an additional transfer via breastfeed-
ing, rather than a de novo synthesis by those too young
animals. Indeed, the human milk was shown to contain
anti-enterovirus antibodies that can neutralize the virus
in vitro [41] and protect newborns from infection [42].
Although not a common diagnostic strategy, the detec-
tion of anti-CV-B5 antibodies in the amniotic fluid has
been reported [43], hence the idea of including such
sample in our analysis that, all the same, gave negative
results. Although maternally transferred neutralizing
antibodies could be responsible for the protection of our
pups from morbidity and mortality, they did not prevent
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vertical transmission of the virus to them, as dis-
cussed below.
Considering the fact that the virus needs 1 to 2 days to
reach fetuses [29, 30, 32] and that offspring born to dams
inoculated 1 day before delivery escape from infection
[28], only tissues from offspring delivered at day 19G and
day 20G were considered in the analysis for virus infection
following inoculation at day 17G.
Here we investigated CV-B4 vertical transmission by
two complementary approaches, viral RNA detection and
viral progeny titration (to evaluate virus replication). Both
methods were concordant since revealing the same high
proportion of infected offspring (18/18 and 11/12 follow-
ing inoculation at day 10G and day 17G, respectively, de-
tails not shown in the results of progeny titration). In a
previous study with CD-1 mice orally inoculated with CV-
B3, virus could be recovered from fetal tissue in only a
small percentage (3 to 13%) of pregnancies [33].
CAR is highly expressed in several fetal organs, which
explains the increased susceptibility of fetuses, but equally
of pregnant dams, to CV-B infections [15, 34, 35]. Several
tissues can be targeted during in utero CV-B4 Infection.
Virus detection in fetuses is a direct proof of antenatal
in utero virus transmission. This is supported by virus
detection in key tissues in vertical transmission (uterus,
amniotic sac, amniotic fluid, placenta and umbilical
cord). Otherwise, perinatal transmission during delivery
cannot be excluded and is often supported by the rein-
crease of viral titers after birth.
Infection of dams’ uteri was evidenced by viral RNA
detection and virus isolation in the current study, and
virus isolation in a previous one [32]. An investigation
outlining the involvement of CAR in the susceptibility to
CV-B3 in ICR mice, showed that CAR is highly
expressed in the epithelium and glands of the uterine
endometrium [15], thus, making the uterus a privileged
target for CV-B, as observed in the investigation of
Modlin & Crumpacker [32].
Virus detection in the amniotic fluid has already been
reported in humans [2], but the current investigation
gives for the first time an evidence of infection of the
mouse amniotic sac and amniotic fluid.
Virus detection in the placenta and the umbilical cord,
and at levels comparable to those in fetal tissues,
strengthens in utero virus transmission through the trans-
placental way. Indeed, it was outlined that the placenta is
a target for CV-B3 and CV-B4 [29, 30, 32, 33]. The failure
of detecting the virus 7 days p.i. in some samples is not so
intriguing since it has already been reported that virus in-
fects the placenta 1 to 2 days after maternal infection but
persists at important levels only 3 to 4 days [32].
CV-B4 E2 detection in offspring’s pancreas seems ra-
ther evident for that so-called diabetogenic strain that is
well known for its pancreotropism [44].
Viral RNA and progeny detection in offspring’s hearts
is equally not surprising since, in addition to be a main
target of CV-B4, the fetal heart highly expresses CAR.
That latest plays an essential role in early cardiac devel-
opment and regulates cardiac remodeling in the embryo
[35, 45]. Indeed, CAR-knock-out mice die in the 11th
gestational day due to cardiac anomalies [35, 46].
Our experimental model is the first to describe virus per-
sistence following vertical transmission, since viral RNA
could be detected until 50 and 70 days postpartum in the
heart and the pancreas, respectively. In previous studies,
CV-B3 [29] and CV-B4 [30] inoculated during the third
week of pregnancy, were found in fetal tissues for a period
that never exceeded 3 to 4 days. In the investigation by
Bopegamage et al., [22], who equally used RT-PCR, no trace
of infection was evident 30 days postpartum and authors
did not search for the virus before that time point (what let
them think that even vertical transmission did not occur).
Virus persistence is considered as one of the main mecha-
nisms leading to the development of chronic diseases asso-
ciated to CV-B infections.
Conclusion
Finally, by addressing numerous issues and combining
several approaches, the current report constitutes a fairly
complete investigation of CV-B vertical transmission
that provides a broader and clearer picture of this still
poorly known contamination route. The actually de-
scribed experimental model not only allows a better un-
derstanding of CV-B infections in fetuses and newborns,
but also constitutes a useful tool to investigate the gen-
esis of CV-B associated chronic diseases, mainly those
with an auto-immune component, such as type 1 dia-
betes, since the autoimmune process is known to be ini-
tiated as soon as fetal life.
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